MP
MFN Partners Portfolio holdings
AUM
$4.67B
This Quarter Return
+4.15%
1 Year Return
+18.61%
3 Year Return
+159.09%
5 Year Return
+255.66%
10 Year Return
–
AUM
$630M
AUM Growth
+$630M
(+10%)
Cap. Flow
+$52.6M
Cap. Flow
% of AUM
8.34%
Top 10 Holdings %
Top 10 Hldgs %
91.03%
Holding
18
New
3
Increased
3
Reduced
2
Closed
–
Top Buys
| 1 |
AGN
Allergan plc
AGN
|
$41.9M |
| 2 |
Cyclerion Therapeutics
CYCN
|
$17M |
| 3 |
Liberty Global Class C
LBTYK
|
$16.6M |
| 4 |
GTT
GTT Communications, Inc.
GTT
|
$4.4M |
| 5 |
XPO
XPO
|
$3.96M |
Top Sells
| 1 |
PG&E
PCG
|
$27.5M |
| 2 |
Navient
NAVI
|
$5.54M |
Sector Composition
| 1 | Healthcare | 38.31% |
| 2 | Communication Services | 19.91% |
| 3 | Energy | 13.03% |
| 4 | Utilities | 10.19% |
| 5 | Financials | 10.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $151M | 23.92% |
900,101
+250,000
| +38% | +$41.9M |
|
2
Fox Class A
FOXA
$26.6B
| $86.8M | 13.78% |
2,369,331
| – | – |
|
|
3
PG&E
PCG
$33.6B
| $64.2M | 10.19% |
2,800,000
-1,200,000
| -30% | -$27.5M |
|
4
Ironwood Pharmaceuticals
IRWD
$214M
| $54M | 8.58% |
4,939,541
| – | – |
|
|
5
XPO
XPO
$15.3B
| $52.8M | 8.39% |
913,935
+68,435
| +8% | +$3.96M |
|
6
Cheniere Energy
LNG
$53.1B
| $51.3M | 8.15% |
750,000
| – | – |
|
7
Goldman Sachs
GS
$226B
| $35.6M | 5.65% |
173,811
| – | – |
|
|
PXD
8
DELISTED
Pioneer Natural Resource Co.
PXD
| $30.8M | 4.88% |
200,000
| – | – |
|
|
FG
9
DELISTED
FGL Holdings Ordinary Shares
FG
| $25.2M | 4% |
3,000,000
| – | – |
|
|
GTT
10
DELISTED
GTT Communications, Inc.
GTT
| $22M | 3.49% |
1,250,000
+250,000
| +25% | +$4.4M |
|
|
11
Cyclerion Therapeutics
CYCN
$7.91M
| $17M | 2.7% |
+1,487,874
| New | +$17M |
|
|
12
Liberty Global Class C
LBTYK
$4.07B
| $16.6M | 2.63% |
+625,558
| New | +$16.6M |
|
13
Takeda Pharmaceutical
TAK
$47.3B
| $13.9M | 2.21% |
785,000
| – | – |
|
|
14
Navient
NAVI
$1.36B
| $3.34M | 0.53% |
244,300
-405,700
| -62% | -$5.54M |
|
15
Aclaris Therapeutics
ACRS
$209M
| $3.29M | 0.52% |
1,500,000
| – | – |
|
16
Evolus
EOLS
$494M
| $1.75M | 0.28% |
+120,000
| New | +$1.75M |
|
|
RVNC
17
DELISTED
Revance Therapeutics, Inc.
RVNC
| $597K | 0.09% |
46,000
| – | – |
|
18
Bristol-Myers Squibb
BMY
$96B
| – | – |
0
| – | – |
|